In the last few years, immunotherapy has showcased quite effective in treating a large number of cases of cancer. However, the brain tumors have remained very stubborn-resistant. A new research study has suggested that a slow-developing brain tumor that is developing in patients has been affected by neurofibromatosis type 1. This may be quite vulnerable to immunotherapy that is likely to provide the immune system with a positive boost for fighting cancer.
The findings of the research study, which has been made by the team of researchers at the Vagelos College of Physicians and Surgeons at Columbia University has been recently published in Nature Medicine. As per the study, around 100,000 individuals in the U.S. have neurofibromatosis type 1, which is a genetic disease that can also result in the development of the tumors across the nervous system. This includes a type of brain tumor, known by the name of glioma. Most of the times children usually have a slow-developing type of glioma; on the other hand, adults have a comparatively aggressive type.
Furthermore, whether they are slow-developing or not, the gliomas are considered as very difficult to treat. Many of the highly resistant to chemotherapy and further radiotherapy can aggravate or rather relieve the symptoms, including seizures and headaches. As the tumors engulf the delicate brain regions, then surgery is quite a rare option. Immunotherapy has been quite successful till date for some of the patients with lymphoma, melanoma, and some other types of cancer. However, in general, the clinical trials have also showcased that it is quite ineffective for brain cancers.